grant

Biomarker Core

Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 1 Jul 2019Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY2025A β-42A β42A-beta 42A-beta42AD dementiaAD detectionAD related dementiaADRDAbeta-42Abeta42AddressAfrican AmericanAfro AmericanAfroamericanAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer disease detectionAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's and related dementiasAlzheimer's biomarkerAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's detectionAlzheimer's diagnosisAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease biological markerAlzheimer's disease diagnosisAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAlzheimers DementiaAlzheimer’s biological markerAlzheimer’s disease biomarkerAmentiaAmyloid beta-42Amyloid beta42Amyloid β-42Amyloid β42Amyloidβ-42Amyloidβ42AssayAstroproteinAβ-42Aβ42BioassayBiological AssayBiological MarkersBiologyBlackBlack raceBlood PlasmaBlood SerumCausalityCerebrospinal FluidClinicClinicalClinical TrialsCognitionCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCommunitiesDataData Management and Analysis CoreData Management and Statistical Analysis CoreData Management and Statistical CoreData SetDementiaDevelopmentDiagnosisDiagnosticDiseaseDisorderDisparitiesDisparityDisturbance in cognitionEthnic OriginEthnicityEtiologyExonsFTLDFloridaFrontal Temporal Lobar DegenerationFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationGFA-ProteinGFAPGenomicsGlial Fibrillary Acid ProteinGlial Fibrillary Acidic ProteinGlial Intermediate Filament ProteinGoalsGrantHealthHeterogeneityHispanicImpaired cognitionIndividualInvestigatorsLB diseaseLB disorderLatino PopulationLatino groupLatino individualLatino peopleLatinosLeadLewy BodiesLewy Body DiseaseLewy body disorderLewy diseaseLewy disorderLiquid substanceMT-bound tauMeasuresNAC precursorNon-HispanicNonhispanicNot Hispanic or LatinoPARK1 proteinPARK4 proteinParticipantPathologicPathologyPatientsPb elementPerformancePharmacodynamicsPlasmaPlasma SerumPredispositionPrimary Senile Degenerative DementiaProcessProteinsRaceRacesResearchResearch PersonnelResearch ResourcesResearch SpecimenResearchersResourcesReticuloendothelial System, Serum, PlasmaRiskSNCASNCA proteinSamplingSerumSpecimenSurrogate MarkersSusceptibilityTAR DNA binding protein 43 kDa pathologyTAR DNA binding protein 43 pathologyTAR DNA binding protein of 43 proteinopathyTAR DNA-binding protein 43TDP-43TDP43TDP43 associated neurodegenerationTDP43 associated neurodegenerative diseaseTDP43 associated pathologiesTDP43 induced neurodegenerationTDP43 neurodegenerationTDP43 neurodegenerative diseaseTDP43 neuropathologyTDP43 pathogenesisTDP43 pathologyTDP43 proteinopathyTDP43 related neurodegenerationTDP43 related pathologyTrans active response DNA binding protein 43 pathologyTrans active response DNA binding protein of 43 kDa proteinopathyTranscriptValidationVascular Cognitive ImpairmentWorka-syna-synucleinalpha synucleinalpha synuclein genealphaSP22assay developmentasynbio-markersbiologic markerbiomarkerbiomarker evaluationcausationcerebral spinal fluidcerebrovascular contribution to cognitive impairmentcerebrovascular contributions to cognitive dysfunctionclinical diagnosisco-morbidco-morbiditycognitive dysfunctioncognitive losscohortcomorbiditydementia burdendepositorydetection assaydevelopmentaldisease causationfluidfunctional lossheavy metal Pbheavy metal leadimprovedinterestliquidmarker evaluationmicrotubule bound taumicrotubule-bound taumixed dementiamixed etiology dementiamixed pathology dementiamixed type dementiamultiple etiology dementiamultiple pathology dementiamultiple type dementianeural imagingneuro-imagingneuroimagingneurological imagingneuropathologicneuropathologicalneuropathologynew markernon A-beta component of AD amyloidnon A4 component of amyloid precursornovel biomarkernovel markeroutreachp-taup-τphospho-tauphospho-τphosphorylated taupost-translational modification of tauposttranslational modification of tauprimary degenerative dementiaprognosticprognostic performanceprotein TDP-43protein TDP43racialracial backgroundracial originrecruitrepositorysenile dementia of the Alzheimer typesocial health determinantsspinal fluidstructural determinantsstructural factorssurrogate bio-markerssurrogate biomarkerssynergismtargeted agenttautau Proteinstau factortau phosphorylationtau posttranslational modificationtau-1trans active response DNA binding protein 43 kDa pathologytrans active response DNA binding protein 43 proteinopathyvalidationsvascular and cognitive impairmentvascular cognition impairmentvascular cognitive declinevascular cognitive diseasevascular cognitive disordervascular cognitive dysfunctionvascular contributions to cognitive declinevascular contributions to cognitive impairmentvascular disease and impaired cognitionvascular dysfunction resulting in cognitive declinevascular related cognitive declinevascular related cognitive impairmentweb sitewebsiteα synuclein geneα-synα-synucleinτ Proteinsτ phosphorylation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

REVISED PROJECT SUMMARY – BIOMARKER CORE The overall goal of the Biomarker Core is to collect, bank, and distribute fluid biospecimens and to generate and share extensive biomarker datasets with the scientific community to address the heterogeneity and improve diagnosis for Alzheimer’s disease (AD) and AD-related dementias (ADRD). Indeed, the Mayo…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Biomarker Core — MAYO CLINIC ROCHESTER | UNITED STATES | Jul 2019 | Dev Procure